Anusha Sivaramakrishnan
Executive Director, Head - Enterprise Project Management and Governance
Arvinas
New York, United States
My organisation
About me
My organisation
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com.
Speaker sessions (3)
Wednesday, 16 October 2024
11:00 - 11:30
PANEL DISCUSSION: Organizational processes behind decision making
- Deciding On The Right Mix Of Therapeutic Areas
Thursday, 17 October 2024
08:30 - 09:00
CASE STUDY: Selecting a Project Portfolio Management (PPM) software as a tool for governance and risk management
- Governance And Risk Management
15:30 - 16:00
PANEL DISCUSSION: Incorporating diversity and inclusion across organization
- Break-Out Sessions